GRAIL to Present at the 2026 Jefferies Global Healthcare Conference
Rhea-AI Summary
GRAIL (Nasdaq: GRAL) announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 7:35 a.m. ET.
Live and replay webcasts will be available in the investor relations section of GRAIL's website for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – GRAL
In the May 22 session, GRAL declined 0.99%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 05 | Q1 2026 earnings | Positive | +15.3% | Reported revenue and Galleri growth with improved loss metrics. |
| Apr 30 | Investor conference notice | Neutral | -0.8% | Announced BofA Securities 2026 Health Care Conference presentation. |
| Apr 22 | Earnings date announcement | Neutral | -3.7% | Set timing for first quarter 2026 results and webcast details. |
| Apr 21 | ASCO data presentations | Positive | +1.8% | Planned presentation of late-breaking NHS-Galleri and PATHFINDER 2 results. |
| Apr 07 | Epic integration news | Positive | +3.3% | Announced Galleri test integration into Epic EHR for broad access. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and data catalysts generally saw aligned positive price reactions.
Over the past months, GRAIL reported Q1 2026 results with revenue growth and increased Galleri test volume on May 5, 2026, which was followed by a positive price reaction. Earlier, the company announced upcoming Q1 results, multiple conference presentations, and plans to present large NHS-Galleri and PATHFINDER 2 datasets, as well as integration of Galleri into the Epic EHR for roughly 450 health systems. These updates outline a trajectory of commercial expansion, major clinical data readouts, and growing visibility, with today’s conference notice fitting into that ongoing investor outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in
For more information, visit grail.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-to-present-at-the-2026-jefferies-global-healthcare-conference-302779216.html
SOURCE GRAIL, Inc.